Yuyao Biotech
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Yuyao Biotech - overview
Established
2020
Location
Shanghai, -, China
Primary Industry
Biotechnology
About
Based in Shanghai, China, and established in 2020, Shanghai Yuyao Biotechnology Co. , Ltd. , trading as Yuyao Biotech is a biotechnology company that provides new drugs for tumors. It has more than 50 employees, and members have master's degrees and above accounting for 60% of employees.
As well as it owns over 20 invention patents. Moreover, its offices and labs cover 5,000 square meters. In November 2025, Yuyao Biotech raised a venture funding from new investor Xiangjiang Xincheng Fund. Yuyao Biotech provides EP4 receptor small molecule antagonists, based on the GPCR drug development platform, and Al-assisted development platform, which are used for advanced cancer, including colon cancer, prostate cancer, and stomach cancer.
EP4 receptor small molecule antagonists have entered phase I clinical trials. The company's revenue is generated by providing drugs which are applied in the treatment of lung cancer, prostate cancer, pancreatic cancer, gastrointestinal tumors, autoimmune diseases, and neurodegenerative diseases.
Current Investors
LC Ventures, Starlight Hesheng, Mingyu Ventures
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals, Bioinformatics, Oncology/Cancer Treatment
Verticals
Artificial Intelligence, Big Data, Cloud Computing
Company Stage
Early Stage
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.